Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 11/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516535 | 0.87 | NOS1 (1.00) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL5512351 | 0.85 | NOS1 (0.75) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL6814034 | 0.84 | NOS1 (0.56) | NOS1ADK | |
| Water SCHEMBL6484545 | 0.84 | NOS1 (0.73) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL5513451 | 0.84 | NOS1 (1.00) | NOS1PIK3CGDHFR | |
| SCHEMBL6913741 | 0.83 | NOS1 (0.54) | NOS1ADK | |
| SCHEMBL5510752 | 0.83 | NOS1 (0.72) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| Water SCHEMBL6484322 | 0.82 | NOS1 (0.70) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL5514521 | 0.81 | NOS1 (1.00) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL8813951 | 0.80 | PIK3CG (0.72) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | claimed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | claimed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | claimed |
| EP-1658081-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-05-24 | — | — | EP | claimed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | claimed |
| WO-2005021003-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2005-03-10 | — | — | WO | claimed |
| EP-1144412-B1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-09-29 | — | — | EP | claimed |
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2004-04-22 | — | — | US | claimed |
| EP-1144412-A1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. Leuven Research & Development (BE) | 2001-10-17 | — | — | EP | claimed |
| WO-2000039129-A1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-07-06 | — | — | WO | claimed |
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-08-24 | — | — | US | disclosed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| US-6844343-B1 | Nitric oxide synthase inhibitors; strokes | VASOPHARM BIOTECH GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2004-04-22 | — | — | US | disclosed |
| EP-1216246-A1 | N-SUBSTITUTED 4-AMINOPTERIDINES, SYNTHESIS AND USE THEREOF AS PHARMACEUTICAL AGENT | Vasopharm Biotech GmbH & Co. KG (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001021619-A1 | N-SUBSTITUTED 4-AMINOPTERIDINES, SYNTHESIS AND USE THEREOF AS PHARMACEUTICAL AGENT | VASOPHARM BIOTECH GMBH & CO. KG (DE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | NOS1 141/4885PIK3CG 1880/4885PIK3CA 1012/4885 |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | NOS1 141/4885PIK3CG 1880/4885PIK3CA 1012/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | NOS1 47/4885PIK3CG 2581/4885PIK3CA 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.